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Abstract
Reviews on the cost/outcome of donor human milk (DHM) for infants requiring care
in the neonatal intensive care unit (NICU) setting have been undertaken. However,
the cost-effectiveness evidence is unclear. Therefore, we conducted a systematic
review of published full economic evaluations of DHM versus standard feeding in
infants in neonatal care with the aim of undertaking a narrative synthesis of the cost-
effectiveness evidence and critical appraisal of the methods used. MEDLINE,
EMBASE, Web of Science, Cochrane Library, Centre for Reviews and Dissemination
(CRD) and PROSPERO databases were searched. Studies were included if they were
full economic evaluations (model-based or trial-based), the participants were infants
in neonatal units requiring nutritional support, the intervention was DHM and the
comparator was any standard feeding option. There were no restrictions on outcome
measures. Two authors independently assessed eligibility, extracted data, assessed
quality and cross-checked results, with disagreements resolved by consensus. Infor-
mation extracted focused on study context, and economic evaluation methods and
results. Of 2861 studies, seven were included. Six (86%) studies originated from
high-income countries. Four (57%) of the studies were model-based. Although we
could not directly compare the different studies, due to the heterogenous nature of
health and economic parameters used in the studies, all DHM interventions indicated
cost-effective or cost saving results. This review suggests that economic evaluation
of DHM interventions is an expanding area of research. Although these interventions
show promise, future economic evaluations of DHM interventions need to explicitly
provide more details on long-term costs and consequences.
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1 | INTRODUCTION
Maternal breast milk is a natural prophylactic and is associated with
improved infant outcomes in lowering the incidence of severe
complications of preterm birth, such as necrotising enterocolitis
(NEC), neonatal infections and retinopathy of prematurity (ROP)
(Fengler, Heckmann, Lange, Kramer, & Flessa, 2020). This supports
mother's own milk (MOM) as the optimal choice for infants
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(National Institute for Health and Care Excellence [NICE], 2008;
World Health Organization [WHO], 2011). However, mothers with
premature or low birthweight (LBW)/very low birthweight (VLBW)
infants may not be able to (1) produce enough milk and (2) breastfeed
due to being HIV positive or having breast cancer or they may have
died during childbirth (Murguia-Peniche & Kirsten, 2014). In these cir-
cumstances, the World Health Organization (WHO) and others
(e.g., the European Society for Paediatrics Gastroenterology and
Nutrition) recommend using DHM that provides a number of benefits
over formula milk, such as a lower risk of NEC in the infant due to the
presence of active enzymes and anti-infective properties in the
breastmilk (Arslanoglu et al., 2013; WHO, 2011). A recent Cochrane
review reported that feeding infants DHM reduced the risk of NEC by
approximately two-thirds compared with formula milk (Quigley,
Embleton, & McGuire, 2018). Another study indicated that feeding
DHM may reduce the risk of bronchopulmonary dysplasia (BPD)
(Villamor-Martínez et al., 2018).
The use of DHM is not common and not all preterm infants who
are likely to benefit receive DHM, as it is more expensive than for-
mula milk (Fengler et al., 2020; Hagadorn, Brownell, Lussier, Parker, &
Herson, 2016; Place, 2010; Zipitis, Ward, & Bajaj, 2015). Availability
of DHM is also a limiting factor. For example, some European coun-
tries have only one or two milk banks (European Milk Bank
Association, 2020). A recent systematic review indicated that DHM is
likely to provide short-term cost savings by reducing the incidence of
NEC (Buckle & Taylor, 2017). However, the cost-effectiveness of
DHM is still unclear.
This paper reports on a systematic review of published full eco-
nomic evaluations of DHM versus standard feeding in infants in neo-
natal care with the aim of undertaking a narrative synthesis of the
cost-effectiveness evidence, appraising the methods used and
assessing the quality of the economic evaluations using the Consoli-
dated Health Economic Evaluation Reporting Standards (CHEERS)
(Husereau et al., 2013) and Phillips (Philips, Bojke, Sculpher, Claxton,
& Golder, 2006) checklists. To our knowledge, this is the first system-
atic review of published full economic evaluations of DHM.
2 | METHODS
The systematic review follows the reporting guidelines of Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
(Liberati et al., 2009). The protocol is registered with the international
prospective register of systematic reviews (PROSPERO) database (ref-
erence number CRD42019139251).
2.1 | Search strategy
The following electronic databases were searched: MEDLINE (Ovid);
MEDLINE in-process and non-index citations; EMBASE (Ovid); Web
of Science; all Cochrane Libraries; Centre for Reviews and Dissemina-
tion (CRD): (Database of Abstracts of Reviews of Effects [DARE], the
National Health Service Economic Evaluation Database [NHS EED],
Health Technology Assessment [HTA]); and PROSPERO. The original
searches were conducted on 19 September 2019, and auto alerts
were set up until 30 June 2020 to identify any additional studies since
the searches were conducted. There was no limitation regarding the
year of publication, and all published records were searched. Search
strategies included Medical Subject Headings (MeSH) terms and text
words of key papers that were identified beforehand. Search strate-
gies that were developed for MEDLINE were adapted as appropriate
for the other bibliographic databases with additional supplementary
searches carried out as necessary. Searches of grey literature and
screening of reference lists in relevant identified articles were also
performed to identify potential additional studies. The MEDLINE sea-
rch strategy is presented in Data S1.
2.1.1 | Eligibility criteria
Studies were included or excluded based on the following criteria:
• Types of study/article: full economic evaluations were included
(studies in which both the costs and the outcomes of the alterna-
tives are examined and in which a comparison of two or more
interventions or case alternatives are undertaken) including trial-
based and model-based evaluations. All five types of economic
evaluations (cost-benefit analysis [CBA], cost-consequence analysis
[CCA], cost-effectiveness analysis [CEA], cost-minimisation analy-
sis [CMA], and cost-utility analysis [CUA]) were included. Partial
economic evaluations, systematic reviews, meta-analyses, qualita-
tive studies, conference abstracts, editorials, short commentary
and study protocols were excluded.
• Participants/population: infants in neonatal units requiring nutri-
tional support—new-born, premature and those of LBW and
Key messages
• Feeding infants with DHM reduces the risk of necrotising
enterocolitis by approximately two-thirds compared with
formula milk.
• In comparison with formula milk, the use of DHM in the
clinical setting is uncommon. Barriers to the use of DHM
may be the high cost and/or lack of availability.
• This study is novel as it is the first study to review the
methods used for full economic evaluations in this field.
• This review suggests that economic evaluations of DHM
interventions is an expanding area of research. Although
all studies indicated that DHM interventions are cost-
effective or cost saving, the review found that there was
heterogeneity with respect to methods used, and further
research and transparency is needed.
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VLBW—and neonatal units offering nutritional support to infants
were included.
• Intervention(s) and exposure(s): DHM for infant feeding where a
mother is unable to provide breast milk or where there is insuffi-
cient supply of breast milk to sustain the infants' nutritional
requirements.
• Comparator(s)/control: all alternative infant feeding options includ-
ing infant formula—of any variety (fortified and unfortified); MOM
with formula milk were included.
• Outcome(s): no restrictions on outcomes measures. Potentially
relevant costs, effectiveness and cost-effectiveness outcomes
were as follows: costs of the DHM provision, direct medical care
costs, direct non-medical costs, indirect costs, societal costs, inci-
dence of feeding intolerance, weight gain, incidence and severity
of NEC and any other infections, duration of hospital stays,
incremental cost-effectiveness ratios (ICER) (e.g., cost per
disability-adjusted life year [DALY] averted, cost per quality-
adjusted life year [QALY] gained, additional DHM cost per case
of averted NEC).
• Other criteria: there were no restrictions based on evaluation per-
spective taken, time horizon for evaluation and country where the
studies were conducted. No setting was formally defined within
the search for this intervention, but premature babies and those
with LBW/VLBW are routinely managed in neonatal units
(Hagadorn et al., 2016).
2.2 | Study selection procedure
The review followed a two-stage method. First, two reviewers inde-
pendently screened the titles and abstracts of all publication records
identified by the searches against the selection criteria. Disagree-
ments were resolved by retrieval of the full publication and consensus
agreement or discussion with a third reviewer. Second, full copies of
all studies deemed potentially relevant were obtained, and two
reviewers independently assessed these with respect to the inclusion/
exclusion criteria. Records rejected at full text stage, and reasons for
exclusion were documented. The literature search results were
exported into EndNote X9 Reference package (Thomson Reuters,
Philadelphia, PA, USA).
2.3 | Data extraction
The study characteristics and findings were extracted by one
reviewer, using an electronic, pre-existing cost-effectiveness form,
which was adapted for extracting data for this systematic review. The
whole process was independently checked for completeness and
accuracy by a second reviewer. Extracted information included the
following:
• Details of study context (authors, publication year, country, setting,
data source, study population, intervention and comparators).
• A detailed account of the economic evaluation methods and results
(type of economic evaluation, outcome measures, model type,
study perspective, time horizon, currency and price year, discount
rate, resource use/costs, analytical methods, results, sensitivity
analyses, generalisability, conclusion, source of funding and con-
flicts of interest).
Missing data were requested from study authors.
2.4 | Quality assessment of included studies
To allow a comparison of the economic evaluation methods used in
the studies, the reporting quality of both the trial-based and model-
based economic evaluations were assessed using the CHEERS check-
list (Husereau et al., 2013), which is a commonly used generic quality
assessment tool of reporting standards. The quality of each model-
based economic evaluation was further assessed using the Philips
checklist (Philips et al., 2006) to provide more specific data for a spe-
cific audience (e.g., health economists' modellers). The quality assess-
ment checklists provide a systematic and critical descriptive overview
of key methodological elements. Quality assessment was undertaken
by one reviewer and was independently checked for completeness
and accuracy by a second reviewer.
3 | RESULTS
Figure 1 illustrates the flow of papers identified, screened and
included in the review. Of the 5559 studies identified in the initial lit-
erature search, 2861 were screened. From the screened papers, 2818
were excluded based on titles and abstracts. Forty-three articles were
considered potentially relevant and remained for subsequent detailed
assessment. Of these, seven were in line with the eligibility criteria.
Therefore, these articles were included in the analysis and synthesis.
The most common reasons for exclusion were non-eligible study/arti-
cle type or non-eligible intervention. Full details of the excluded stud-
ies are presented in Data S2.
3.1 | Details of study context
Full details of study context are presented in Table 1. A large propor-
tion of the studies (n = 6) were published between 2012 and 2019
(Assad, Elliott, & Abraham, 2016; Dritsakou et al., 2016; Ganapathy,
Hay, & Kim, 2012; Hampson, Roberts, Lucas, & Parkin, 2019; Taylor,
Joolay, Buckle, & Lilford, 2018; Trang et al., 2018), apart from one
published in 2002 (Arnold, 2002). The vast majority of the studies
(n = 6) originated from high-income countries, mainly the United
States (n = 4) (Arnold, 2002; Assad et al., 2016; Ganapathy
et al., 2012; Hampson et al., 2019), with one each from Canada (Trang
et al., 2018) and Greece (Dritsakou et al., 2016). The Organisation for
Economic Co-operation and Development (OECD) defines
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high-income countries as those with a gross national income (GNI) per
capita of US$12,375 or more, with upper middle-income countries as
those with a GNI per capita between US$3996 and US$12,374
(OECD, 2019). Only one study was from an upper middle-income
country—South Africa (Taylor et al., 2018). In terms of study setting,
all took place in NICU settings. More than half of the economic evalu-
ations (n = 4) were model-based (Arnold, 2002; Ganapathy
et al., 2012; Hampson et al., 2019; Taylor et al., 2018) compared with
trial-based evaluations (Assad et al., 2016; Dritsakou et al., 2016;
Trang et al., 2018).
The number of participants in each study differed considerably.
For trial-based studies, this ranged from 200 (Dritsakou et al., 2016)
to 363 (Trang et al., 2018); and for model-based studies, ranged from
410 (Arnold, 2002) to 10,000 (Taylor et al., 2018). Apart from two
(29%) studies which included LBW infants (Assad et al., 2016;
Dritsakou et al., 2016), the remainder only included VLBW or
extremely premature (EP) infants (Arnold, 2002; Ganapathy
et al., 2012; Hampson et al., 2019; Taylor et al., 2018; Trang
et al., 2018). As per our inclusion criteria, all interventions were DHM.
A range of comparators were identified, such as MOM.
3.2 | Review of economic evaluation methods and
results
A detailed account of the economic evaluation methods and results is
presented in Tables 2, 3 and 4.
3.2.1 | Type of economic evaluation and outcome
measures
Focusing on the methods of economic evaluation, more than half of
the studies (n = 4) performed a CCA (Assad et al., 2016; Dritsakou
et al., 2016; Ganapathy et al., 2012; Hampson et al., 2019) and used a
broad range of outcome measures including: duration of hospital stays
(Assad et al., 2016; Dritsakou et al., 2016; Ganapathy et al., 2012;
Hampson et al., 2019); incidence and severity of NEC (Assad
et al., 2016) and other infections such as sepsis (Hampson
et al., 2019), viral infection (Dritsakou et al., 2016); incidence of feed-
ing intolerance (Assad et al., 2016); duration of enteral gavage feeding
(Dritsakou et al., 2016); time to full feed (Assad et al., 2016); weight
F IGURE 1 PRISMA flow diagram for the selection of studies
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gain (Assad et al., 2016); and NICU (Dritsakou et al., 2016; Ganapathy
et al., 2012), NEC (medical and surgical) (Ganapathy et al., 2012;
Hampson et al., 2019), sepsis (Hampson et al., 2019) and
hospitalisation costs (Assad et al., 2016; Dritsakou et al., 2016;
Ganapathy et al., 2012; Hampson et al., 2019). Of the remaining three
(43%) studies, one conducted a CMA (Arnold, 2002) using savings to a
health care system or individual family for NEC/sepsis prevention.
Another conducted a CEA (Trang et al., 2018) using incidence of NEC,
hospitalisation and post discharge costs and additional DHM cost per
case of averted NEC. The final study conducted a CUA (Taylor
et al., 2018) using the incidence and severity of NEC, and cost per
DALY averted.
CMA focuses solely on costs' differences therefore questions
such as ‘Is the extra effectiveness worth the extra cost?’ cannot be
answered (Hoch & Dewa, 2005). One particular study conducted a
CMA, effectiveness data were taken from a single, non-randomised
study comparing the use of fortified MOM with formula (Schanler,
Shulman, & Lau, 1999). They assumed the effectiveness outcomes to
be equal for DHM and MOM because there was a lack of available
effectiveness data for DHM. This is problematic as DHM is unlikely to
be as effective as MOM (Renfrew et al., 2009). Measurement and val-
uation of DALY were not reported in the CUA study (Taylor
et al., 2018).
3.2.2 | Type of modelling approach taken
With respect to modelling, one study used three models for the cost-
effectiveness analysis (Arnold, 2002); another a single cost-
effectiveness model (assumed to be a decision model) (Ganapathy
et al., 2012); a third used a decision tree model (Hampson
et al., 2019); and the fourth a probabilistic cohort Markov decision
model (Taylor et al., 2018). The studies by Taylor et al. (2018) and
Hampson et al. (2019) justified their model choice. The remaining two
model-based studies did not provide any justification for their model
choice (Arnold, 2002; Ganapathy et al., 2012).
3.2.3 | Evaluation perspective taken, time horizon
considered and price year/currency
All studies clearly reported their study perspective. The majority
(n = 5) were from a healthcare perspective (Arnold, 2002; Assad
et al., 2016; Dritsakou et al., 2016; Ganapathy et al., 2012;
Taylor et al., 2018); two (29%) were from a societal perspective
(Hampson et al., 2019; Trang et al., 2018). The time horizons of the
studies differed, ranging from 2 months for the model-based study by
Arnold (2002) to 18 months for the trial-based study by Trang
et al. (2018). None of these studies justified their choice of time hori-
zon. One (14%) study only stated the enrolment time frame for the
infants (Assad et al., 2016). Two (29%) studies did not explicitly state
their time horizon (Ganapathy et al., 2012; Hampson et al., 2019).
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TABLE 3 Detailed account of the economic evaluation methods and results—Part 2
Authors, year Analytical methods
Results (incremental costs and
outcomes)
Arnold, 2002 Three models of cost analysis, statistical
analysis methods: Not stated
Model 1: $8800 could be saved per
infant, every $1 spent on DHM leads
to a save of $11–$37 in NICU costs.
Model 2: save of $48,150 in additional
hospital stay days, assuming that each
infant is discharged 15 days earlier.
Model 3: a case of confirmed NEC not
requiring surgery cost: additional
$138,000 per infant and a case of NEC





STATA statistical software version 13:
Fisher's exact test and linear regression
analyses
Feeding intolerance, number of days to
full feeds and incidence of NEC were
lower, and total hospitalisation costs
were lower by up to $106,968 per
infant in those fed an EHM diet
compared with other groups. Average
weight gain per day was similar among
the four groups (18.5 to 20.6 g per
day). Mixed group had the highest





SPSS version 19: independent Student's t
test, Mann–Whitney test, Chi-squared
test, Fisher's exact test, and logistic
regression analyses
Infants fed with their mother's milk had
significantly shorter hospital stays and
lower hospitalisation costs. In group I
infants, the duration of enteral feeding
was shorter, resulting in significantly
lower costs. Up to 8 months of age,
group I infants experienced fewer
episodes of viral infections, and cost of
each doctor visit and drug prescription




Excel 2003: cost calculator for the model
and a separate analysis of hospital
discharges
Incremental costs of medical/surgical
NEC over/above average costs
incurred for EP infants without NEC:
$74,004 and $198,040 per infant,
respectively. EP infants fed with 100%
human milk-based: lower NICU length
of stay and total costs of
hospitalisation: Savings of 3.9 NICU
days and $8167/EP infant
One-way/two-way percentage changes
in parameters. Cost savings from
donor HMF strategy were sensitive
to price/quantity of donor HMF,
percentage reduction in risk of
overall and surgical NEC achieved




Microsoft excel: decision tree model:
main analysis, or ‘base case’,
sensitivity analyses
EHMD substantially reduces mortality/
improves other health outcomes, as
well as generating substantial cost
savings of $16,309 per infant by
reducing adverse clinical events. Cost
savings increase to $117,239 per
infant when wider societal costs are
included. Holding other factors
constant, EHMD would still reduce
costs if baseline incidence of NEC in
usual care group was as low as 7%
(1) Various threshold analyses to
explore incidence rates of late onset
sepsis/NEC: EHMD to be cost
saving. (2) Lower/higher cost
scenarios. (3) Some examples of
wider societal costs. (4) Case where
mortality for usual care group was
estimated from retrospective cohort
study, with treatment effect of
EHMD on mortality taken from trial
Taylor
et al., 2018
Microsoft excel: cohort Markov decision:
various scenario analyses
Prioritising infants in lowest birthweight
groups: Save the most lives, whereas
prioritising infants in highest
birthweight groups: the highest cost
savings. All allocation scenarios would
be considered very cost-effective in
South Africa compared with use of
Probabilistic SA. Dirichlet distribution:
proportion of infants; beta
distribution: risk of NEC with formula
milk; log normal distribution: relative
risk of any NEC with donor milk or
relative risk of surgical NEC with
donor milk
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did not (Arnold, 2002; Assad et al., 2016; Dritsakou et al., 2016). All
studies reported their currency. For the study by Taylor et al. (2018)
costs were converted to 2015 US Dollars at Purchasing Power Parity
(PPP) using the World Bank exchange rates.
3.2.4 | Choice of discount rate
For less than half of the studies (n = 3) (Arnold, 2002; Dritsakou
et al., 2016; Taylor et al., 2018), discounting was not appropriate as
the time horizons were less than 1 year (Drummond, Sculpher,
Claxton, Stoddart, & Torrance, 2015). Three (43%) studies did not
state a discount rate (Assad et al., 2016; Ganapathy et al., 2012; Trang
et al., 2018), whereas one (Hampson et al., 2019) reported using an
annual discount rate of 3%, for both costs and benefits as rec-
ommended by the US Second Panel on Cost-Effectiveness in Health
and Medicine (Sanders et al., 2016).
3.2.5 | Resource use and costs
The choice of inclusion of a particular type of resource use and cost
varied according to the study purpose, perspective, time horizon and
the nature of the intervention/comparator being evaluated. Costs
tended to be categorised into direct medical care costs (e.g., NICU,
NEC treatment [medical and surgical], sepsis and hospitalisation costs)
(Arnold, 2002; Assad et al., 2016; Dritsakou et al., 2016; Ganapathy
et al., 2012; Hampson et al., 2019; Taylor et al., 2018; Trang
et al., 2018); informal and non-medical care costs (e.g., caregiver trans-
portation and labour market earnings lost) (Trang et al., 2018); indirect
costs incurred by institutions (e.g., administration, human resources
and plant operations) (Trang et al., 2018); societal costs (Hampson
et al., 2019; Trang et al., 2018); enteral feeding costs
(Dritsakou et al., 2016; Trang et al., 2018); parenteral feeding costs
(Dritsakou et al., 2016); and resource use and costs of the DHM/other
diet provision such as formula milk (detailed information is presented
in Table 2) (Arnold, 2002; Assad et al., 2016; Dritsakou et al., 2016;
Ganapathy et al., 2012; Hampson et al., 2019; Taylor et al., 2018;
Trang et al., 2018).
Only two (29%) studies stated the costs which were excluded
from their costing. These were discharges with an average daily cost
of <$100 and infants who died within the first 3 days of life for the
study by Ganapathy et al. (2012) and costs to parents and society and
long-term health service costs by Taylor et al. (2018).
3.2.6 | Sensitivity analysis undertaken
Fewer than half of the studies (n = 3) did not perform any type of sen-
sitivity analysis to assess the robustness of their results (Arnold, 2002;
Assad et al., 2016; Dritsakou et al., 2016). One of the trial-based stud-
ies conducted a deterministic sensitivity analysis (Trang et al., 2018),
whereas three of the model-based studies conducted at least one
type of sensitivity analysis in line with recommendations. These were
one-way and two-way percentage changes in the parameters used to
build the expected costs calculator (Ganapathy et al., 2012); four sen-
sitivity analyses to explore the impact on the results if alternative
input values were used in the model (Hampson et al., 2019) and a
probabilistic sensitivity analysis (Taylor et al., 2018).
3.2.7 | Narrative synthesis of cost-effectiveness
evidence
We cannot compare results of economic evaluations that assess
health care interventions, which have been conducted in different
TABLE 3 (Continued)
Authors, year Analytical methods
Results (incremental costs and
outcomes)




SAS version 9.4: nonparametric
regression analyses for costs,
Cochran–mantel–Haenszel statistics
for outcomes, linear regression
statistics or Wilcoxon rank tests for
continuous outcomes
Incidence of NEC differed between
groups (all stages 3.9% DHM, 11.0%
PTF; P = 0.01). Costs to 18 months did
not differ with a mean of 217,624 and
217,245 in DHM and PTF groups.
Incremental cost: 379. Post discharge
costs were lower in DHM 46,440 than
PTF group 55,102 (P = 0.04). DHM
cost an additional $5328/case of
averted NEC (ICER: $5328 per case of
averted NEC)
Deterministic SA. Costs excluding
infants: received exclusively mother's
milk during intervention and infants:
had incomplete family
questionnaires. ICER: DHM costs,
formal medical costs, physician fees
from birth to 18 months, caregiver
wages to reflect Ontario minimum
wage and national Canadian wage,
and NEC stage ≥II instead of NEC
stage ≥I as health outcome. Scatter
plots/CEACs
Abbreviations: CEACs, cost-effectiveness acceptability curve; DALY, disability-adjusted life year; DHM, donor human milk; EHM, entirely human milk;
EHMD, exclusive human milk diet; EP, extremely premature; HMF, human milk fortifier; ICER, incremental cost-effectiveness ratio; NEC, necrotizing
enterocolitis; NICU, neonatal intensive care unit; SA, sensitivity analysis.
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regions/settings and times. This is due to notable differences in the
funding of health care systems, the treatments and care pathways,
and baseline population and demographic characteristics around the
world. Despite the heterogenous methods of economic evaluations
used prohibiting direct comparison between studies, all DHM inter-
ventions indicated cost-effective or cost saving results. The costs
saved in each study, using DHM, differed considerably. This ranged
from $8167 (Ganapathy et al., 2012) to $238,000 (Arnold, 2002) per
infant.
Arnold (2002) stated that three models of cost analysis were
presented to indicate the savings that could accrue to a health care
system or individual family if banked donor milk were provided as first
feedings when MOM was not available. Model 1 noted that $8800
could be saved per infant (every $1 spent on DHM could lead to a
saving of $11–$37 in NICU costs). Model 2 indicated that there would
be a saving of $48,150 in additional hospital stay days, assuming that
each infant was discharged 15 days earlier. Model 3 showed that a
case of confirmed NEC not requiring surgery would cost an additional
$138,000 per infant, and a case of NEC requiring surgery would cost
an additional $238,000 per infant. Therefore, they concluded that the
cost of using banked donor milk to feed premature infants is relatively
inconsequential when compared with the savings from NEC
prevention.
Assad et al. (2016) noted that implementing an entirely human
milk (EHM) diet in VLBW infants resulted in a significant decrease in
the incidence of NEC (1.10% in the EHM group vs. 10% in the bovine
and mixed groups, P < 0.011). Other benefits of this diet included
reductions in feeding intolerance, time to full feeds, length of hospital
stay, and hospital and physician charges (by up to $106,968 per
infant) for EP and VLBW infants.
Dritsakou et al. (2016) concluded that LBW infants fed predomi-
nantly with their mother's milk supplemented with donor milk had sig-
nificantly lower hospital stays (mean length of stay 21 vs. 26 days,
P < 0.001) and NICU/hospitalisation costs. In these infants, the dura-
tion of enteral gavage feeding was shorter, and they experienced
fewer episodes of viral infections.
The results by Ganapathy et al. (2012) indicated that EP infants
fed a 100% human milk-based diet had lower expected NICU length
of stay and hospitalisation costs, resulting in net direct savings of
almost four NICU days and $8167 per EP infant.
The analysis by Hampson et al. (2019) determined that an exclu-
sive human milk diet (EHMD) reduces mortality and improves other
health outcomes, as well as generating substantial cost savings of
$16,309 per infant by reducing adverse clinical events. Cost savings
increase to $117,239 per infant when wider societal costs are
included. Holding other factors constant, an EHMD would still reduce
costs if the baseline incidence of NEC in the usual care group was as
low as 7%.
Taylor et al. (2018) concluded that prioritising infants in the low-
est birthweight groups would save the most lives, whereas prioritising
infants in the highest birthweight groups would lead to the highest
cost savings. All allocation scenarios would be considered very cost-
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‘worst case’ ICER was $619 per DALY averted. However, the analysis
could be extended by taking a longer time horizon, using data from
more than one country and exploring the use of DHM as an adjunct
to MOM.
The findings by Trang et al. (2018) indicated that incidence of
NEC was significantly lower in the DHM (3.9%) compared with the
preterm formula (PTF) group (11.0%). Post discharge costs were sig-
nificantly lower in the DHM $46,440 compared with the PTF group
$55,102. DHM cost an additional $5328 per case of averted NEC
(ICER: $5328 per case of averted NEC). However, total costs from a
societal perspective to 18 months of providing supplemental DHM
versus PTF to VLBW infants did not vary.
3.2.8 | Generalisability
Three (43%) of the studies did not report any information regard-
ing the generalisability of their results (Assad et al., 2016;
Dritsakou et al., 2016; Ganapathy et al., 2012). There were various
points of view regarding the generalisability of findings by the
remaining studies. It was noted by Arnold (2002) that costs saved
could be applied to other quality health care services which would
decrease disparity of care, including improving breastfeeding educa-
tion and support among women from minority populations who ini-
tiate breastfeeding at much lower rates. Hampson et al. (2019)
pointed out that as the clinical and resource use data are all spe-
cific to the US, no strong conclusions on the generalisability of
their findings to other settings can been made. However, cost sav-
ings of their analysis suggests that it is worth investigating the
likelihood that an EHMD is cost-effective in other settings. Data
from the study by Taylor et al. (2018) was based on clinical data
provided by one hospital, and there might be differences between
hospitals even within a single country. The authors mentioned that
although published data for some parameters exist for high income
countries, mostly the US, these data cannot be applied to many
middle-income settings because of the lack of specialist neonatal
equipment. Trang et al. (2018) noted that the extent to which the
findings are generalizable to other settings is uncertain.
3.3 | Quality assessment of the included studies
The quality assessment results are presented in Table 5. The quality
of both the trial-based and model-based economic evaluations was
assessed using the CHEERS checklist (Husereau et al., 2013)—a
26-item instrument with a total of six domains. None of the included
studies fulfilled all of the quality criteria although none were ranked
as ‘worthless’. More than half of the studies fulfilled a large number
of the quality criteria. The criteria which were least well addressed
were the assumptions, the characterising uncertainty and heterogene-
ity, the generalisability and the source of funding. The quality of any
model-based economic evaluations was further assessed using the
Philips checklist (Philips et al., 2006). Only two of the studies fulfilled
a large number of the quality criteria according to the Phillips check-
list. The criteria that were least well addressed were the justifications,
the assumptions, the uncertainties and the heterogeneity.
4 | DISCUSSION
To the best of our knowledge, this is the first study to conduct a sys-
tematic review of the methods used for published full economic eval-
uations of DHM versus standard feeding in infants in neonatal care.
The scaling up of breastfeeding can help to prevent an estimated
823,000 child deaths and 20,000 breast cancer deaths every year
(Victora et al., 2016).
TABLE 5 Critical appraisal of the economic evaluation studies using the CHEERS and Philips checklists
Authors, year














Arnold, 2002 14 5 5 2 14/26 16 10 17 10 3 16/56
Assad
et al., 2016
15 7 2 2 15/26
Dritsakou
et al., 2016
14 7 2 3 14/26
Ganapathy
et al., 2012
19 4 2 1 19/26 14 12 18 7 5 14/56
Hampson
et al., 2019
22 1 2 1 22/26 31 6 11 7 1 31/56
Taylor
et al., 2018
21 1 3 1 21/26 36 6 8 2 4 36/56
Trang
et al., 2018
21 3 0 2 21/26
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The review identified some emerging patterns. We found that
among the economic evaluations, all DHM interventions indicated
cost-effective or cost saving results. The majority of the studies
reported clinical outcome measures (e.g., incidence of NEC). Only one
of the seven studies (Taylor et al., 2018) reported health-related out-
come measures (e.g., DALY) commonly used within economic evalua-
tions. None of the included studies explicitly reported that they were
CBA. However, four of them applied a CCA approach with costs
saved as an outcome, which is a form of CBA. Consideration of a
broader range of outcomes going beyond the health sector allows for
inclusion of benefits and costs from multiple sectors. Efforts are being
made to adapt and develop methodologies to promote the use of this
type of economic evaluation (Frew, 2017).
Model-based evaluations offer the opportunity to improve the
generalisability of findings and assess the longer term costs and bene-
fits of DHM versus standard feeding. They are important as they are
widely used as policy-making tools that can inform resource allocation
decisions. However, none of the model-based studies offered data
based on a longer time horizon, and furthermore, the results from one
of these studies was based on a small sample size (Arnold, 2002). Fur-
thermore, two of the studies did not make explicit mention of
procedures for checking their models (Arnold, 2002; Ganapathy
et al., 2012), and one study did not assess the sensitivity of their find-
ings to the model choice (Arnold, 2002). More importantly, the clinical
and resource use data are all specific to one country. Therefore, the
generalisability of findings to other contexts, particularly from devel-
oped to developing country settings, would be questionable
(Musgrove & Fox-Rushby, 2006).
More than half of the evaluations in this review either did not
apply a discount rate, because it was not applicable, or applied one
which was a recommended discount rate according to the relevant
country guidelines. Three remaining studies did not apply a discount
rate. Of those, one had a stated time horizon (Trang et al., 2018). The
other two did not state a time horizon, making it difficult to judge if
they (Assad et al., 2016; Ganapathy et al., 2012) neglected to follow
discounting guidelines.
Methods for collecting resource use and the type of costs
included were found to differ across the studies. The majority of the
studies did not report what cost components were excluded from
their estimates. Future studies should clearly specify which costs are
included and excluded. Informal and non-medical care costs, indirect
costs and societal costs were only collected by two studies (Hampson
et al., 2019; Trang et al., 2018). It is considered good practice to
report findings both with and without informal/indirect costs. Includ-
ing these types of costs (e.g., costs incurred by families) may alter the
management recommendations. To be able to determine the macro-
economic benefits of DHM by reducing the incidence of NEC, an
analysis of the lifetime costs would be useful. However, a lifetime
model for the economic impact of DHM versus formula feed would
be subject to extreme assumptions, which would introduce excessive
uncertainties. Establishing causality in this area is extremely challeng-
ing and relies on huge amounts of data, which may not even exist.
Longitudinal analysis is an option; however, it is costly and slow.
It is inevitable that an economic evaluation contains some degree
of uncertainty in its assessment. In order to assess the level of uncer-
tainty, one can apply various sensitivity analyses, which are a set of
techniques that seek to analyse how sensitive the results are to uncer-
tain parameters. The choice of sensitivity analysis may depend on the
methodology applied, type of economic evaluation (trial-based or
model-based) or the setting in which the intervention was conducted.
However, three of the studies did not perform any type of sensitivity
analysis to assess the robustness of their results, and no justification
for the exclusion was given (Arnold, 2002; Assad et al., 2016;
Dritsakou et al., 2016).
Two of the model-based studies (Arnold, 2002; Ganapathy
et al., 2012) did not have sufficient methodological quality to provide
convincing evidence of the cost-effectiveness of DHM. Also, although
all DHM interventions in this review appear cost-effective or even
cost saving using standard rules of cost-effectiveness, there is varia-
tion by intervention design. However, the narrative synthesis of the
cost-effectiveness evidence, appraising the methods applied and
assessing the quality of the included studies are useful for informing
health economists/modellers and future research direction in
this area.
4.1 | Comparison with previous systematic
reviews
The main intervention being evaluated in Renfrew et al. economic
evaluations' review (Renfrew et al., 2009) was the provision of a
lactation consultant to help mothers breastfeed their own infants.
The use of DHM, as an adjunct to MOM, was considered in a sec-
ondary analysis. However, this comparison was not between exclu-
sive use of DHM and exclusive use of formula. The study by
Buckle and Taylor (2017) reviewed cost and cost-effectiveness of
DHM to prevent NEC. Therefore, they mainly focused on one par-
ticular outcome. They also only included one full economic evalua-
tion based on their research question and the date they conducted
their review. They concluded that it is likely that the use of DHM
is cost-effective; however, they suggested that to strengthen the
evidence base, there is a need for conducting comprehensive full
economic evaluations of the use of DHM versus standard feeding
in infants.
In general, the two previous reviews mainly focused on cost anal-
ysis and partial economic evaluations, and summarised and compared
the costs and outcomes of a range of interventions and comparators
(Buckle & Taylor, 2017; Renfrew et al., 2009). Neither of them
reviewed the full economic evaluation methods in the way they have
been outlined in this paper. By imposing no restrictions on outcome
measures, findings of this study showed that all DHM interventions
indicated cost-effective or cost saving results. Additionally, appraising
the methods of full economic evaluations adds to the literature as it
provides researchers with detailed information of the methods applied
in each study which could help them to produce high quality and use-
ful research.
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4.2 | Strengths and limitations of this review
One of the most important strengths of this systematic review is the
comprehensive search strategy used which contained a broad range
of electronic databases of published studies. Furthermore, there were
no country restrictions. There was one publication from South Africa
as a middle-income country. Also, this review considered a wide range
of evaluations: the use of DHM with different durations versus other
standard feeding options. All the major short- and long-term health
and associated cost consequences related to the use of DHM com-
pared with standard feeding options were considered. In addition,
more than half of the studies fulfilled a large number of the quality
criteria.
Our review also had some limitations. We only included full eco-
nomic evaluations. Therefore, some important data contained within
partial evaluations might have been missed. The shortcomings of the
included studies and underlying evidence base were further limita-
tions. Synthesising the evidence base was challenging due to the het-
erogeneous nature of the methods applied. Potential publication bias
may also be a problem. It is possible that any study that did not find
positive evidence of the use of DHM did not conduct an economic
evaluation or, if they did, failed to get it published.
4.3 | Challenges associated with conducting
economic evaluations in this space
Researchers in this space usually will not calculate DALYs or QALYs
gained. This is due to the short time frames and because they cannot
survey the infants with preference-based measures that are needed in
order to derive utilities. The utility measures most appropriate for
these analyses would be the DALYs or QALYs gained/lost by the par-
ents of the infants. Also, capturing particularly long-term health and
non-health costs and consequences of DHM interventions is challeng-
ing. There are additional other challenges including: lack of funding,
scarcity of robust local clinical data, sourcing unit costs and managing
lack of equivalent threshold values for outcome gains.
5 | CONCLUSIONS
This systematic review suggests that economic evaluation of DHM
interventions is an expanding area of research, and current economic
evaluations are mainly set in developed countries. All DHM interven-
tions indicated cost-effective or cost saving results. However, the
review found heterogeneity with respect to the economic evaluation
methods used. So, to strengthen the evidence base further and
increase comparability across interventions, we recommend a com-
prehensive approach to evaluate cost-effectiveness to capture, partic-
ularly, long-term health and non-health costs and consequences of
DHM. Furthermore, a careful description should be provided of how
the costs of DHM have been generated and its implications on
healthcare.
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